Background Sustained tachycardia causes left ventricular (LV) systolic dysfunction leading to heart failure (HF), which is widely known as "tachycardia-induced cardiomyopathy (TIC)", but its prevalence and prognosis in Japanese remain unclear.
Methods and Results
Of 213 consecutive patients with HF associated with atrial fibrillation (AF) requiring hospitalization (n=213) between January 1999 and December 2004, and 104 (83 males, 67±12.6 years) were identified as not having any structural heart disease. Of them 41 (39%) had a normal LV ejection fraction (LVEF) at the initial admission, and the remaining patients fell into 2 groups: those with rapid (<6 months) normalization of the LVEF after AF management (presumed TIC, 30 patients, 29%) and those with persistent LV systolic dysfunction (dilated cardiomyopathy (DCM), 33 patients, 32%). Although the B-type natriuretic peptide value and LVEF did not differ between the 2 groups, the LV size on admission was significantly smaller in the TIC group (LV end-diastolic dimension (LVDd) 57.6±7.2, LV end-systolic dimension (LVDs) 49.4±8.0) than in the DCM group (LVDd 63.4±8.8, LVDs 55.3±9.6, p<0.05). During a follow-up period of 42.1±21.2 months, cardiac death and recurrent HF hospitalization were significantly less frequent in the TIC group than in the DCM group. Conclusions In AF-associated HF requiring hospitalization, TIC is the presumed cause in approximately onethird of patients without any previously known structural heart disease. That particular group is characterized by a relatively smaller LV and better prognosis under medical treatment. 
I
The present study focused on patients without diagnosed structural heart disease and they were classified into 3 groups using the data form admission and also after discharge, on the basis that the diagnostic criteria for TIC have not been established and also that idiopathic DCM without a previously established diagnosis is difficult to be differentiate from TIC during hospitalization. The 3 groups were: (1) Group A (lone AF presumed as the sole cause of the HF): preserved systolic function during hospitalization, defined as LV ejection fraction (LVEF) on admission UCG of ≥50%; 15 (2) Group B (TIC presumed present): impaired systolic function that rapidly normalized during hospitalization or after discharge, defined as LVEF <50% on admission, which improved to ≥50% within 6 months after discharge; 9, [16] [17] [18] [19] [20] and (3) Group C (DCM presumed present): impaired systolic function that persisted for 6 months or more after discharge, defined as LVEF <50% on admission and which remained <50% for 6 months or more after discharge. LVEF was determined by the Pombo method from the LV end-diastolic (LVDd) and end-systolic (LVDs) dimensions. We measured the LV diameter (LVDd and LVDs) when the heart rate variability had stabilized and measured it 3 times non-consecutively and obtained the mean value of those measurements.
Treatment
All patients were treated to decrease the heart rate or given diuretics and/or vasodilators, bed rest, oxygen, and anticoagulant therapy during the acute phase and switched to oral medications, such as diuretics, digitalis, angiotensinconverting enzyme-inhibitor, angiotensin-receptor blocker, -blockers, and antiarrhythmic drugs. The dosages of the drug infusions, were titrated at the discretion of the attending physicians according to the patient's condition and were in the conventional dosage range used in Japan. Neither catheter ablation nor rhythm-or rate-control therapy was performed. However, cardioversion was performed as necessary.
Follow-up
The patients without known structural heart disease were followed-up monthly in the outpatient clinic after discharge. During the follow-up period, all medications were determined according to the judgment of the attending physicians. UCG was recorded every 3 months for the first 6 months and thereafter as appropriate. Using the parasternal long-axis view to assess the ventricular dimensions, the LVEF was calculated by the Pombo method. The average follow-up period was 42.1±21.2 months (range 12-84 months), and the clinical outcome, including cardiovascular deaths and hospitalization because of HF, was determined from the medical records.
Statistical Analysis
Continuous variables and categorical variables are expressed as the mean ± SD and were compared using ANOVA, multiple comparisons and the chi-square test as appropriate. All p-values were 2-sided, and a p-value less than 0.05 was considered to indicate statistical significance.
Results

Patient Characteristics
A total of 213 patients were admitted for AF-associated HF from January 1999 to December 2004 and of these 109 (51%) had a previously diagnosed structural heart disease and 104 (49%, 83 males, 67±12.6 years old) presented with AF-associated HF without any known cause.
The 104 patients were classified into 3 groups according to the study criteria and were proved to be almost homogeneously distributed: Group A (n=41, 74.3±8.8 years old), Group B (n=30, 63.4±11.7 years old), and Group C (n=33, 62.1±13.5 years old) ( Table 2) . Therefore, our classification suggested that lone AF, TIC and DCM would be possible causes of the HF in approximately one-third of the patients with an unknown origin. The age and sex significantly differed among the groups; Group A was characterized by an older age and female prevalence, but these 2 parameters did not significantly differ between Groups B and C.
Serum BNP Level and UCG Parameters
The average serum BNP value on admission in Groups A, B and C was 360±306 pg/ml, 629±545 pg/ml and 773± 467 pg/ml, respectively (Table 2) . Although the value tended to be slightly lower in Group A, the difference did not reach a statistical significance.
In Group A, which had a normal LVEF on admission, the LVDd and LVDs were both within normal limits, as expected. In contrast, both the LVDd and LVDs were significantly larger in Groups B and C than in Group A (Table 2) . Moreover, the magnitude of the enlargement differed between Groups B and C, and both values were significantly smaller in Group B than in Group C (p<0.05 for both LVDd and LVDs). The left atrial dimension on admission did not significantly differ among the 3 groups.
Clinical Outcome
There were no significant differences among the 3 groups with regard to the treatment regimens (Table 3) . When we compared Group B with the other groups, the medication content decreased monthly and, in particular, the diuretics were decreased in 12 patients (40%) and -blocker in 8 (26.7%) after 6 months. During the follow-up period, radiofrequency ablation was not performed in any patients. During a mean follow-up period of 42.1±21.2 months, cardiovascular deaths occurred in 2 (4.9%), 0 (0%) and 5 (15.2%) patients in Groups A, B and C, respectively, and there was a statistically significant difference between Groups B and C (p<0.05, Table 2 ). Recurrent HF requiring hospitalization occurred in 10 (24.4%), 3 (10.0%) and 14 (42.4%) patients, respectively ( Table 2) . The Group B patients were significantly less prone to develop recurrent HF than those in Group C (p<0.05, Table 2 ). In the Group B patients, a rate control strategy was adopted in 18 (60%) patients (Table 3) , but the clinical outcome (cardiovascular deaths and recurrent HF hospitalization) did not significantly differ from the other patients under a rhythm control strategy with antiarrhythmic drugs. The change in heart rate and rhythm did not have a significant difference, but when we compared Group B with the other groups, we found sinus rhythm was maintained (Table 4 ). Recurrent HF developed in all groups when the heart rate was greater than 80 beats/min.
Discussion
Major Findings
The major findings are (1) that of the patients with AF and HF requiring hospitalization, approximately half of them will not have a structural heart disease with a previous diagnosis on admission, (2) that in the patients without any known structural heart disease, lone AF, presumed TIC, and DCM are almost homogeneously distributed, and (3) that the presumed TIC group is characterized by a smaller LV and better prognosis as compared with the DCM group. Because detailed epidemiological data on TIC in Japan are not available, the present study is the first to demonstrate the prevalence and clinical characteristics of TIC in Japanese patients with AF and HF. In previous studies, the prevalence of AF in HF has been reported to range widely from 13% to 27%. 8, [21] [22] [23] [24] [25] [26] [27] Conversely, the incidence of HF among AF subjects was 33 per 1,000 person-years. 25 Although AF and HF are closely related to each other, their temporal relationships are complex: AF itself causes HF, and HF could easily cause AF. The concept of TIC was developed to explain the mechanism of AF causing HF, and previous studies have reported that TIC could comprise approximately 25-50% of AF-associated HF. [11] [12] [13] [14] Although there are no such epidemiological data in Japan, the present study identified the diverse etiology of AF-associated HF. Approximately half of the present patients had previously diagnosed structural heart diseases. Because lone AF, TIC, and DCM occurred in approximately one-third of the remaining patients, respectively, TIC would be the primary cause of HF in 14% (30 among 213 patients) of patients with AF-associated HF, which is a substantial percentage.
Although the existence of TIC is well known, it is difficult to differentiate from DCM and is usually determined retrospectively when the impaired wall motion improves a few months later after appropriate control of the causal arrhythmia has been achieved. 9, [16] [17] [18] [19] [20] Previous studies in which TIC was diagnosed retrospectively from the follow-up observations have failed to demonstrate any useful criteria for early diagnosis during the HF state. In the present study as well, we could not determine any specific clinical parameters for diagnosing TIC. The BNP value, LVEF, and left atrial dimension on UCG did not significantly differ between the TIC and DCM groups. However, the LV dimensions were significantly smaller in the TIC group than in the DCM group, which could provide some help in the differentiation in the future.
The cause of the different LV size between TIC and DCM is unclear but deserves discussion. Because enlargement of the LV is compensatory and time-dependent, the difference in the size could reflect disease progression. TIC is believed to occur in the short term. A previous study reported that AF for 2 weeks resulted in TIC. Such a short period of HF would limit the enlargement of the LV. In contrast, DCM is believed to be a slowly progressive disease that is latent for a relatively long time before hospitalization, and during that time the compensatory processes would result in enlargement of the LV. In other words, hospitalization is the result of failure of the compensatory mechanisms of DCM. However, these considerations are as yet hypothetical, and need to be determined from more detailed observations of the natural history of TIC and DCM from their initiation. The prognosis is believed to be excellent for TIC, because the impaired systolic function is reversible under appropriate management of the causal arrhythmia with a rhythm or rate control strategy. 1, 3, 5, 7, 9, 14, 28 In the present study the rate of cardiac death and recurrent hospitalizations for HF was lower than for patients with DCM. However, a recent report has suggested a risk of sudden death in this particular group 27 and experimental studies also provide some evidence for the worse outcome. 29 However, in the present study, no cases of sudden cardiac death occurred in the TIC group and the reason for this is unknown. However, amiodarone is not used in Japan and may be related to the discrepancy in the results.
Study Limitations
First is the diagnosis of TIC, which was retrospectively performed from normalization of the systolic function. Therefore, some patients in the TIC group might have had early-phase DCM that responded quickly to medical treatment. However, at present, no other definite criteria are available for TIC. Another approach from the viewpoint of the degree of LVEF improvement after AF control may be useful. Second is the relatively small number of patients with presumed TIC. Third is the relatively short follow-up period. When a larger number of patients are followed up for a longer time, the mortality rate for TIC might be interpreted differently. Although limited for these reasons, the present study has clarified the basic epidemiological information on AF and HF requiring hospitalization in Japanese patients and thus assists in the construction of a therapeutic strategy.
Conclusions
In AF-associated HF requiring hospitalization, TIC is presumably the cause in approximately one-third of the patients without any known structural heart disease. This particular group is characterized by a relatively smaller LV on admission and better prognosis under medical treatment, as compared with those with DCM. Cautious observation with an appropriate AF management is mandatory in this particular group.
